A first-in-class CRISPR-CasX gene editor silencing APOC3 transcription for the treatment of Severe Hypertriglyceridemia Post author: Post published:August 16, 2026 Post category: Continue ReadingA first-in-class CRISPR-CasX gene editor silencing APOC3 transcription for the treatment of Severe Hypertriglyceridemia
Microglia replacement therapy for CSF1R-related Leukoencephalopathy Post author: Post published:August 16, 2026 Post category: Continue ReadingMicroglia replacement therapy for CSF1R-related Leukoencephalopathy
TY1 and Semaglutide to Treat Cardiometabolic HFpEF Post author: Post published:August 16, 2026 Post category: Continue ReadingTY1 and Semaglutide to Treat Cardiometabolic HFpEF
CRISPR/Cas9-mediated gene editing of Hematopoietic stem and progenitor cells for Friedreich’s ataxia Post author: Post published:August 16, 2026 Post category: Continue ReadingCRISPR/Cas9-mediated gene editing of Hematopoietic stem and progenitor cells for Friedreich’s ataxia
Noncoding RNA drug TY2 for arrhythmogenic cardiomyopathy Post author: Post published:August 16, 2026 Post category: Continue ReadingNoncoding RNA drug TY2 for arrhythmogenic cardiomyopathy
